<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NK39RH6L" height="0" width="0" style="display:none;visibility:hidden"></iframe>

Journal: The Lancet. Rheumatology

rabindra.tharu.np@gmail.com

·

September 5, 2024

Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet’s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial

BACKGROUND Data from head-to-head trials of immunomodulatory therapies for Behçet’s disease are scarce. We aimed to compare the efficacy and safety of ciclosporin, interferon alfa-2a, and adalimumab, each combined with corticosteroids, in preventing uveitis relapse in patients with severe Behçet’s disease. METHODS We did a randomised, open-label, assessor-masked, head-to-head trial at a large, specialised uveitis…
rabindra.tharu.np@gmail.com

·

July 12, 2024

Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

BACKGROUND Gout is an inflammatory arthritis manifesting as acute episodes of severe joint pain and swelling, which can progress to chronic tophaceous or chronic erosive gout, or both. Here, we present the most up-to-date global, regional, and national estimates for prevalence and years lived with disability (YLDs) due to gout by sex, age, and location…